0001209191-23-026998.txt : 20230503 0001209191-23-026998.hdr.sgml : 20230503 20230503164544 ACCESSION NUMBER: 0001209191-23-026998 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230501 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Seth Alpna CENTRAL INDEX KEY: 0001721020 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39264 FILM NUMBER: 23884902 MAIL ADDRESS: STREET 1: 614 MCKINLEY PLACE NE CITY: MINNEAPOLIS STATE: MN ZIP: 55413 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Keros Therapeutics, Inc. CENTRAL INDEX KEY: 0001664710 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 811173868 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617-314-6297 MAIL ADDRESS: STREET 1: 1050 WALTHAM STREET, SUITE 302 CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-05-01 0 0001664710 Keros Therapeutics, Inc. KROS 0001721020 Seth Alpna C/O KEROS THERAPEUTICS, INC. 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 1 0 0 0 0 Stock Option (right to buy) 46.07 2023-05-01 4 A 0 20000 0.00 A 2033-04-30 Common Stock 20000 20000 D One-twelfth (1/12th) of the shares subject to the option shall vest in equal quarterly installments commencing on August 1, 2023, subject to the Reporting Person continuing to provide service through each such date. /s/ Keith Regnante, Attorney-in-Fact 2023-05-03